Why Biohaven is back on traders' screens

Biohaven (BHVN) is back in focus after upbeat analyst commentary on its epilepsy drug opakalim, stronger sentiment following a peer’s Phase 3 epilepsy result, and a sector wide reaction to US regulatory leadership changes.

Despite a positive 1 day share price return of 0.59% to US$10.27 after the recent analyst commentary and sector tailwinds, Biohaven’s 30 day share price return of 11.47% and 1 year total shareholder return of 65.08% point to pressure that contrasts with the more upbeat sentiment around opakalim and its broader pipeline.

If this kind of biotech volatility has your attention, it could be worth scanning our screener of 32 healthcare AI stocks as another way to uncover potential ideas in data driven drug development.

With Biohaven trading around US$10.27 after a 1 year total shareholder return of 65.08% and analysts pointing to opakalim and a broad pipeline, is there still mispricing here, or is the market already baking in future growth?

Price to book of 29.7x, is it justified?

Biohaven closed at $10.27, and its valuation sits on a P/B of 29.7x, which is far higher than both peer and industry levels.

P/B compares a company’s market value to its accounting net assets. For a pre revenue, loss making biotech like Biohaven, a high multiple usually reflects how much investors are willing to pay for the pipeline and intellectual property rather than current earnings power.

Here, the gap is wide. Biohaven’s 29.7x P/B is above its peer average of 20.7x and far above the US Biotechs industry average of 2.7x. This signals that the market is assigning a much richer value to its early stage portfolio versus many other names in the space.

Result: Price to book of 29.7x (OVERVALUED)

However, this rich P/B sits against a 1 year total shareholder return decline of 65.08% and a reported net income loss of US$738.822m, which could challenge the bullish pipeline story if sentiment cools.

Next Steps

If this mix of optimism and concern feels hard to balance, it is worth reviewing the full picture yourself and considering how the risk profile stacks up, especially given there are 5 important warning signs that some investors are already watching closely.

Looking for more investment ideas?

If you are serious about building a stronger watchlist, do not stop at one biotech story. Use targeted screens to surface opportunities you might otherwise miss.

• Spot potential value plays by checking our list of 48 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
• Prioritise resilience by reviewing 68 resilient stocks with low risk scores that stand out for more measured risk scores and could suit a steadier approach to equity investing.
• Hunt for earlier stage potential with the 28 elite penny stocks with strong financials that already show stronger financial characteristics than many of their low priced peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.